Kenya - inglese - Pharmacy and Poisons Board

sandoz gmbh biochemiestrasse 106250, austria - hydrochlorothiazide - tablet - 25mg - agents acting on the renin-angiotensin system:

Kenya - inglese - Pharmacy and Poisons Board

sandoz gmbh biochemiestrasse 10a-6250 kundl / tirol austria - amoxixillin trihydrate - powder for oral suspension - amoxicillin 125mg. - beta-lactamantibacterials: penicillins

Kenya - inglese - Pharmacy and Poisons Board

sandoz gmbh biochemiestrasse 106250, austria - ramipril - tablet - 10mg - ramipril

Kenya - inglese - Pharmacy and Poisons Board

sandoz gmbh biochemiestrasse 106250, austria - simvastatin - film-coated tablet - 40mg - plain lipid modifying agents: hmg coa reductase

Egitto - inglese - EDA (Egyptian Drug Authority)

biochemie-egypt - capsule - 150 mg

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - somatropin - turner syndrome; prader-willi syndrome; dwarfism, pituitary - pituitary and hypothalamic hormones and analogues - infants, children and adolescentsgrowth disturbance due to insufficient secretion of growth hormone (gh).growth disturbance associated with turner syndrome.growth disturbance associated with chronic renal insufficiency.growth disturbance (current height standard-deviation score (sds) < -2.5 and parental adjusted sds < -1) in short children / adolescents born small for gestational age (sga), with a birth weight and / or length below -2 standard deviations (sds), who failed to show catch-up growth (height velocity (hv) sds < 0 during the last year) by four years of age or later.prader-willi syndrome (pws), for improvement of growth and body composition. the diagnosis of pws should be confirmed by appropriate genetic testing.adultsreplacement therapy in adults with pronounced growth hormone deficiency. patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. in patients with childhood-onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-i (igf-i) concentrations (sds < -2) who may be considered for one test. the cut-off point of the dynamic test should be strict.

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.mobilisation of peripheral blood progenitor cells (pbpc).in children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.treatment of persistent neutropenia (anc ≤ 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).